Biogen (BIIB) bought an early-stage ALS drug Thursday, so cue up the “sad trombones” if you were hoping for a blockbuster biotech acquisition.

But Spinraza sales rebounded nicely in the fourth quarter and the multiple sclerosis business remains in good shape. Biogen offered 2018 financial guidance a tick higher than consensus.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.